Dilated cardiomyopathy resident survival guide: Difference between revisions
Steven Bellm (talk | contribs) No edit summary |
Steven Bellm (talk | contribs) No edit summary |
||
Line 82: | Line 82: | ||
{{familytree | | | | | | | | E01 | |E01=<div style="text-align: left;"><b><u>Laboratory findings:</u></b><br> | {{familytree | | | | | | | | E01 | |E01=<div style="text-align: left;"><b><u>Laboratory findings:</u></b><br> | ||
❑ Complete blood count | ❑ Complete blood count<br> | ||
❑ Chemistry:<br> | |||
❑ | :❑ Troponin, BNP or NT-proBNP<br> | ||
:❑ Serum electrolytes (including calcium and magnesium) | :❑ Serum electrolytes (including calcium and magnesium)<br> | ||
:❑ Blood urea nitrogen | :❑ Blood urea nitrogen<br> | ||
:❑ Serum creatinine<br> | |||
:❑ Serum creatinine | :❑ Glucose<br> | ||
:❑ Glucose | :❑ Fasting lipid profile<br> | ||
:❑ Liver function tests<br> | |||
:❑ Fasting lipid profile | :❑ Thyroid-stimulating hormone<br> | ||
:❑ Consider Screening for [[hemochromatosis]], [[HIV]], [[rheumatologic diseases]], [[amyloidosis]], or [[pheochromocytoma]]<br> | |||
:❑ Liver function tests | |||
:❑ Thyroid-stimulating hormone | |||
:❑ Consider Screening for [[hemochromatosis]], [[HIV]], [[rheumatologic diseases]], [[amyloidosis]], or [[pheochromocytoma]] | |||
:❑ Urinalysis</div>}} | :❑ Urinalysis</div>}} | ||
{{familytree | | | | | | | | F01 | |F01=A01}} | {{familytree | | | | | | | | F01 | |F01=A01}} | ||
{{familytree | | | | | | | | |!| | | | | | |}} | {{familytree | | | | | | | | |!| | | | | | |}} |
Revision as of 16:41, 5 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Steven Bellm, M.D. [2]
Dilated cardiomyopathy resident survival guide Microchapters |
---|
Overview |
Causes |
Diagnosis |
Treatment |
Do's |
Dont's |
Overview
Dilated cardiomyopathy (DCM) relates to a group of heterogeneous myocardial disorders and is characterized by dilatation and impaired contraction and systolic function of the left or both ventricles. Atrial and/or ventricular arrhythmias can occcur, and there is a risk for sudden death. [1] The weight of the heart is increased but the maximal thicknesses of the left ventricular free wall and septum are usually normal as a result of the abnormally dilated chambers.[2]
Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.[3]
- Life-threatening causes:
- Common causes:
- Idiopathic
- Myocarditis
- Ischemic heart disease
- Infiltrative disease
- Peripartum cardiomyopathy
- Hypertension
- Human immunodeficiency virus (HIV) infection
- Connective tissue disease
- Substance abuse
- Doxorubicin
- Other
Complete Diagnostic Approach
A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.[4]
Symptoms of heart failure | |||||||||||||||||||||||||||||||||
History and symptpms: ❑ Hints for etiology (family history, and others)
| |||||||||||||||||||||||||||||||||
Physical examination: ❑ Vital signs:
❑ General appearance:
❑ Heart:
❑ Lungs:
❑ Abdomen:
❑ Extremities:
| |||||||||||||||||||||||||||||||||
Laboratory findings: ❑ Complete blood count
| |||||||||||||||||||||||||||||||||
A01 | |||||||||||||||||||||||||||||||||
A01 | |||||||||||||||||||||||||||||||||
A01 | |||||||||||||||||||||||||||||||||
B01 | B02 | ||||||||||||||||||||||||||||||||
C01 | |||||||||||||||||||||||||||||||||
Treatment
shown
hidden
Do's
Dont's
References
- ↑ "Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies". Br Heart J. 44 (6): 672–3. 1980. PMC 482464. PMID 7459150.
- ↑ Tazelaar HD, Billingham ME (1986). "Leukocytic infiltrates in idiopathic dilated cardiomyopathy. A source of confusion with active myocarditis". Am J Surg Pathol. 10 (6): 405–12. PMID 3521345.
- ↑ Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL; et al. (2000). "Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy". N Engl J Med. 342 (15): 1077–84. doi:10.1056/NEJM200004133421502. PMID 10760308.
- ↑ Yancy, C. W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D. E.; Drazner, M. H.; Fonarow, G. C.; Geraci, S. A.; Horwich, T.; Januzzi, J. L.; Johnson, M. R.; Kasper, E. K.; Levy, W. C.; Masoudi, F. A.; McBride, P. E.; McMurray, J. J. V.; Mitchell, J. E.; Peterson, P. N.; Riegel, B.; Sam, F.; Stevenson, L. W.; Tang, W. H. W.; Tsai, E. J.; Wilkoff, B. L. (2013). "2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. 128 (16): e240–e327. doi:10.1161/CIR.0b013e31829e8776. ISSN 0009-7322.